Notes
2019 US dollars
Reference
La EM, et al. Budget-Impact Analysis of Ibalizumab in the Treatment of Us Medicare Beneficiaries with Multidrug-Resistant Hiv-1 Infection. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/103049
Rights and permissions
About this article
Cite this article
Budget impact of ibalizumab. PharmacoEcon Outcomes News 855, 5 (2020). https://doi.org/10.1007/s40274-020-6870-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6870-x